CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Revenues:
License and milestone fees	$ 57,815	$ 39,455	$ 24,227
Royalty revenue	13,867	10,346	592
Non-cash royalty revenue related to sale of future royalties	(5,484)
Research and development support	2,848	7,187	7,873
Clinical materials revenue	5,527	2,908	2,843
Total revenues	85,541	59,896	35,535
Operating Expenses:
Research and development	111,768	106,958	87,073
General and administrative	28,228	24,469	21,471
Total operating expenses	139,996	131,427	108,544
(Loss) income from operations	(54,455)	(71,531)	(73,009)
Investment income, net	69	44	126
Non-cash interest expense on liability related to the sale of future royalties	5,437
Other (expense) income, net	(916)	123	72
Net (loss) income	$ (60,739)	$ (71,364)	$ (72,811)
Basic and diluted net loss per common share (in dollars per share)	$ (0.71)	$ (0.83)	$ (0.87)
Basic and diluted weighted average common shares outstanding (in shares)	86,038	85,481	84,063
Total comprehensive loss	$ (60,739)	$ (71,364)	$ (72,811)